Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01894555 · ClinicalTrials.gov registry record · Phase 4
Pharmacogenomics of Antiplatelet Response - II (PARes-II)
A Phase 4 study of Atherothrombosis, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 4
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT01894555 is a Phase 4 study of Atherothrombosis that has completed, run by Johns Hopkins University. The registered enrollment target is 33 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01894555, a Phase 4 study of Atherothrombosis, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial is examining the effect of 4-week aspirin therapy on platelet transcriptome in persons at high-risk for myocardial infarction or stroke due to family history of early-onset coronary artery disease.
Conditions Studied
Interventions
- DRUG Aspirin
Study Locations (1)
Maryland
- Johns Hopkins University School of Medicine - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2013-01 |
| Est. Completion | 2014-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01894555
The ClinicalTrials.gov registry entry for NCT01894555 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atherothrombosis appearing as the primary indexed condition, and to 1 intervention - of which Aspirin is the first listed.
NCT01894555 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT01894555 about?
NCT01894555 is a clinical study titled "Pharmacogenomics of Antiplatelet Response - II (PARes-II)". This clinical trial is examining the effect of 4-week aspirin therapy on platelet transcriptome in persons at high-risk for myocardial infarction or stroke due to family history of early-onset coronary artery disease.
What is the current status of trial NCT01894555?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 33 participants. The study started on 2013-01. Estimated completion is 2014-08.
What conditions does trial NCT01894555 study?
This clinical trial studies the following conditions: Atherothrombosis.
What interventions are being tested in trial NCT01894555?
The interventions under investigation include: Aspirin (DRUG).
Who is sponsoring clinical trial NCT01894555?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01894555 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.